Company Xlife Sciences AG

Equities

XLS

CH0461929603

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Xlife Sciences AG

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 09:00:31 16/05/2024 pm IST			5-day change	1st Jan Change
34.3 ^CHF	-3.11%		-2.83%	-31.26%

23/04	Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	MT
29/02	Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.

Number of employees: 17

CHF in Million	2022	Weight	2023	Weight	Delta
Not Allocated 66.0 %	1	72.8 %	1	66.0 %	-12.81%
Biotechnologies Therapies 34.0 %	0	27.2 %	0	34.0 %	+20.11%

CHF in Million	2022	Weight	2023	Weight	Delta
Switzerland 100.0 %	1	100.0 %	1	100.0 %	-3.85%

Managers	Title	Age	Since
Oliver Baumann CEO	Chief Executive Officer	-	01/19/01
Carl von Halem DFI	Director of Finance/CFO	-	01/21/01
Alexander Zink CTO	Chief Tech/Sci/R&D Officer	-	-
Simone Bonito ADM	Chief Administrative Officer	-	-
Frank Ploger CTO	Chief Tech/Sci/R&D Officer	-	01/20/01
Christian Faber CMP	Compliance Officer	-	12/19/12
Beat Kläui AUD	Comptroller/Controller/Auditor	-	-

Members of the board	Title	Age	Since
Christian Faber CMP	Compliance Officer	-	12/19/12
Mark Müller BRD	Director/Board Member	-	25/18/25
Oliver Baumann CEO	Chief Executive Officer	-	01/19/01
David Deck CHM	Chairman	-	20/22/20
Désirée Dosch BRD	Director/Board Member	-	20/22/20
Norbert Windhab BRD	Director/Board Member	-	20/22/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,703,292	2,838,803 ( 49.77 %)	0	49.77 %

Name	Equities	%	Valuation
Vartex International LLC 23.10 %	1,317,641	23.10 %	46 M CHF
Gilbert Schoeni 20.48 %	1,167,895	20.48 %	41 M CHF
Akira Holding AG 6.465 %	368,700	6.465 %	13 M CHF
OFZL AG 0.1753 %	10,000	0.1753 %	348 907 CHF
CATAM Asset Management AG 0.1403 %	7,999	0.1403 %	279 091 CHF
Gutmann Finanz Strategien AG 0.0359 %	2,048	0.0359 %	71 456 CHF
DWS CH AG 0.0183 %	1,042	0.0183 %	36 356 CHF
State Street Global Advisors France SA 0.0181 %	1,031	0.0181 %	35 972 CHF

Xlife Sciences AG

Talacker 35

8001, Zurich

+41 44 385 84 60

http://www.xlifesciences.ch

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.3 CHF

Average target price

68 CHF

Spread / Average Target

+98.25%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
XLIFE SCIENCES AG	-31.26%	22Cr
MODERNA, INC.	+33.37%	4.95TCr
IQVIA HOLDINGS INC.	+1.55%	4.26TCr
LONZA GROUP AG	+49.11%	4.25TCr
CELLTRION, INC.	-4.22%	2.91TCr
ICON PUBLIC LIMITED COMPANY	+11.57%	2.66TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	1.86TCr
BIO-TECHNE CORPORATION	+7.36%	1.32TCr
MEDPACE HOLDINGS, INC.	+28.30%	1.25TCr
UNITED THERAPEUTICS CORPORATION	+23.80%	1.21TCr

Other Biotechnology & Medical Research